Cobra Wins Adenovirus Contract

Cobra Biomanufacturing has signed an agreement with a European biotechnology company to provide development services for an Adenovirus-based product.Cobra will use its virus purification platform, which is based on scalable chromatographic operations that integrates single use technologies. According to the company, the process shows comparable purities to density gradient approaches and yields of as much as 50%.

Simon Saxby, chief executive officer of Cobra Biomanufacturing, said, “We are very pleased to have been selected by this company as this underlines Cobra’s extensive experience and expertise in producing virus based products for clinical trials. This agreement also highlights Cobra’s continued commitment to be the CMO of choice for virus production.”

Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference